Key Quantitative Figures

  • Number of Warrants Allotted: 16,21,000 (Sixteen Lakhs Twenty-One Thousand)
  • Warrant Issue Price: ₹566 per warrant (inclusive of both Warrant Subscription Price and Warrant Exercise Price)
  • Amount Received: ₹22,93,71,500 (Twenty-Two Crore Ninety-Three Lakh Seventy-One Thousand Five Hundred Only), representing 25% of the total issue price
  • Face Value of Equity Share: ₹5 each
  • Premium on Conversion: ₹551 per share
  • Conversion Period: 18 months from date of allotment (October 13, 2026)
  • Balance Payment Required for Conversion: 75% of Warrant Issue Price

Dates of Action

  • Board Meeting Date: August 13, 2026
  • Shareholder Approval Date: September 17, 2026 (Postal Ballot)
  • BSE Approval Date: October 7, 2026 (Letter No. LOD/PREF/PB/FIP/908/2026-27)
  • NSE Approval Date: October 8, 2026 (Letter No. NSE/LIST/56990)
  • Allotment Date: October 13, 2026 (Operation Committee resolution)

Parties Involved

Allottees (Promoter/Promoter Group):

1. Mr. Rajendra Mutha

2. Krsnaa Diagnostics (Mumbai) Private Limited

Stock Exchanges:

  • BSE Limited
  • National Stock Exchange of India Limited

Company Officials:

  • Sujoy Sudipta Bose, Company Secretary and Compliance Officer

Shareholding Impact

Preferential Allotment Outcome:

| Name | Pre-Allotment Shares | Pre-Allotment % | Post-Allotment Shares | Post-Allotment % |

| Mr. Rajendra Mutha | 80,29,920 | 24.75% | 81,04,920 | 23.11% |

| Krsnaa Diagnostics (Mumbai) Private Limited | 7,65,685 | 2.36% | 23,11,685 | 6.59% |

| Total Promoter Group | 87,95,605 | 27.11% | 1,04,16,605 | 29.70% |

Note: The percentage holding calculation assumes full conversion of all currently outstanding convertible warrants of the company.

Conversion Terms

  • Warrants are fully convertible into one fully paid-up equity share each
  • Conversion may be exercised in one or more tranches within 18 months from allotment date
  • Upon conversion, each warrant holder will be allotted one equity share of face value ₹5 at ₹566 per share (including premium of ₹551)
  • The amount already paid against each warrant will be adjusted against the issue price for the resultant equity share
  • If conversion rights are not exercised within 18 months, the unexercised warrants shall lapse and the subscription amount paid shall be forfeited

Capital Structure Impact

There is no immediate change in the paid-up share capital of the company as only convertible warrants have been allotted at this stage. The capital structure will change only upon actual conversion of warrants into equity shares.

Financial Impact

The company has received ₹22.94 crore as 25% of the total issue price. The balance 75% of the issue price (approximately ₹68.81 crore) will be received upon conversion of warrants within the 18-month period.

#Tags: #KrsnaaDiagnostics #PreferentialAllotment #SEBIRegulation30 #Fundraising #Neutral